Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

NEW HAVEN, Conn., Aug. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that it had accrued a total of 85 patients to the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in previously untreated elderly patients with de novo poor-risk acute myelogenous leukemia (AML).

Alan Kessman, Chief Executive Officer said, "We are extremely pleased to have reached this milestone in the pivotal Phase II trial of our lead anticancer agent. We will now proceed to analyze the data and, if warranted, prepare a New Drug Application for submission to the U.S. Food and Drug Administration in 2008." He added, "We continue to plan on the release of preliminary data from this trial at the American Society of Hematology (ASH) Meeting in December."

The pivotal Phase II trial, initiated in May 2006, is evaluating Cloretazine(R) (VNP40101M) as a single agent in previously untreated AML patients over the age of 60 with de novo poor-risk AML. Patients are eligible for this trial if they are at least 60 years of age with de novo AML and have one of the following additional risk factors: (i) unfavorable cytogenetics; (ii) an ECOG performance status of 2 or greater; or (iii) a co-morbid condition that precludes them from receiving cytotoxic therapy with cytarabine and an anthracycline. Patients over the age of 70 with de novo AML who do not have favorable cytogenetics are also eligible.

The primary endpoint for this trial is the complete response rate (including complete remission (CR) and complete remission with incomplete platelet recovery (CRp)). Secondary endpoints include overall survival, disease-free survival and progression-free survival.

The trial ha
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Calif. , Aug. 20, 2014 ... will be using advanced, ventilator technology from Covidien ... to care for patients. The ... more naturally, compared to conventional mechanical ventilation, and ... soon as possible. Patients on mechanical ventilation are ...
(Date:8/20/2014)... Aug. 20, 2014 Children aren,t the ... vaccinations to help prevent disease. The Centers for ... all adults, but currently, many adults are not ... National Immunization Awareness Month, and the American Lung ... especially those with lung disease, to talk with ...
(Date:8/20/2014)... -- Research and Markets  has announced the addition of ... their offering. Global Market Report of Pralmorelin ... and regionally ( Europe , Asia ... Latin America etc.). It captures Pralmorelin market trends, ... on three primary areas; manufacture methods & technology development, market ...
Breaking Medicine Technology:Torrance Memorial Medical Center Acquires Advanced Ventilator Technology to Enhance Patient Care 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 3Global Market Report of Pralmorelin 2
(Date:8/20/2014)... of chronic users of codeine-containing cough syrups (CCS) ... white matter and associates these changes with increased ... diffusuion tensor imaging (DTI) (an MR imaging technique), ... matter integrity of chronic CCS users. Deficits were ... the inferior fronto-occipital fasciculus, which other studies have ...
(Date:8/20/2014)... News) -- Pigs, hearts transplanted into baboons survived for ... as previously achieved, researchers report. The work is ... organs to shorten transplant waiting lists. In this ... baboons, abdomens. The genetic engineering and new methods of ... the hearts to survive for more than a year. ...
(Date:8/20/2014)... Dennis Thompson HealthDay Reporter ... exercise may help older women avoid a condition that causes ... active postmenopausal women had a 10 percent lower risk of ... researchers report in the Aug. 20 issue of the ... enjoyed this protection against the heart rhythm disorder even if ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The Board ... Perkins Eastman is pleased to announce the ... services in China and the surrounding region. ... Richard Sprow AIA has relocated to the ... career in healthcare planning and design and to better ...
(Date:8/20/2014)... PITTSBURGH, Aug. 20, 2014 A common approach to ... blood did not improve survival chances for people who ... experts at the University of Pittsburgh School of Medicine. ... PLOS One , suggest acute hemodialysis, an aggressive method ... failure, may not provide a definitive benefit to the ...
Breaking Medicine News(10 mins):Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 3Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2
... backboned animals, but recent study has shown that things ... of their skeletal development. These findings will be published ... scientists were able to find the very same protein, ... which is also found in all vertebrates with backbones ...
... that babies breastfed for six months have reduced respiratory ... was conducted by investigators at UC Davis Children's Hospital, ... Pediatrics, Center for Child Health Research. ,In ... Davis Children's Hospital, lead author, "We found that babies ...
... by the Canadian snacks company Frito Lay Canada has launched ... South Asians. ,40 chip flavours created and tested ... and wasabi for test marketing. Stores were stocking these chops ... South Asians annually spends $12.6 billion on retail goods and ...
... technique to test and identify 'dead regions' in the ... children is being developed by Karolina Kluk, a Cambridge ... for development of individualized hearing aids for children. ... patients regarding their sensitivity to a range of tones ...
... skin cancer is the most common tumor to be diagnosed. It ... University Hospital of Navarra. // Sadly, the incidence melanoma has been ... killer of women aged between 19 and 50 years. In the ... 9000 in just 10 years. ,Two main factors regarded ...
... use birth control patch are twice as likely to develop clots ... found. Recently, another study conducted on similar grounds // has revealed ... sides, women who use the patch have been urged to discus ... ,Women who use the patch may be at an increased ...
Cached Medicine News:Health News:New Test Offers Hope in Effective Hearing Aid Design for Babies 2Health News:New Technique Could Revolutionize Melanoma Diagnosis and Treatment 2
... Cascade M-4 is a manual ... all routine clotting assays - PTs, ... Designed for easy, inexpensive, low-volume testing, ... but big on features, offering time ...
... STA is a fully-automated, coagulation workstation ... immunological assays in true random access ... sample management offers high throughput and ... the need to interrupt current testing. ...
... ACL Advance can reduce costs ... lab. With its superior ACL ... easy to use coagulation analyzer ... Plus, the protective transparent cover ...
... Pro Professional Hemoglobin Testing System consists of ... strips, used in measuring total hemoglobin, from ... Pro provides the precision, accuracy and cost ... Pro Professional Hemoglobin Testing System is portable ...
Medicine Products: